参考文献/References:
[1] 刘宗超, 李哲轩, 张阳, 等.2020 全球癌症统计报告解读[J].肿瘤综合治疗电子杂志, 201,7(2):1-13. LIU Zongchao, LI Zhexuan, ZHANG Yang, et al. Interpretation on the report of Global Cancer Statistics 2020 [J]. Journal of Multidisciplinary Cancer Management(Electronic Version), 201,7(2):1-13.
[2] KULIK L,EL-SERAG H B. Epidemiology and management of hepatocellular carcinoma [J].Gastroenterology, 2019 , 156(2):477-491, e1.
[3] 张振, 潘晴, 刘旭, 等.circRNA 与肿瘤发生的研究进展[J]. 现代检验医学杂志,2018,33(2):157-159,164. ZHANG Zhen, PAN Qing, LIU Xu, et al. Research progress of the relationship between circular RNA and tumorigenesis [J]. Journal of Modern Laboratory Medicine,2018,33(2):157-159, 164.
[4] LI Jiao, SUN Dan, PU Wenchen, et al. Circular RNAs in cancer: biogenesis, function, and clinical significance[J]. Trends in Cancer, 2020, 6(4): 319-336.
[5] JIA Guiqing, TANG Youyin, DENG Gang, et al. MiR-590-5p promotes liver cancer growth and chemotherapy resistance through directly targeting FOXO1[J].American Journal of Translational Research, 2019,11(4): 2181-2193.
[6] SUN Wu, WANG Xiaojun, LI Jialu, et al. MicroRNA-181a promotes angiogenesis in colorectal cancer by targeting SRCIN1 to promote the SRC/VEGF signaling pathway[J]. Cell Death & Disease, 2018, 9(4): 438.
[7] HAN D L, WANG L L, ZHANG G F, et al. MiRNA-485-5p, inhibits esophageal cancer cells proliferation and invasion by down-regulating O-linked N-acetylglucosamine transferase[J]. European Review for Medical and Pharmacological Sciences, 2019,23(7): 2809-2816.
[8] FESLER A, JU Jingfang. Development of microRNAbased therapy for pancreatic cancer[J]. Journal of Pancreatology, 2019, 2(4): 147-151.
[9] LIN Wan, MIAO Yu, MENG Xiangkun, et al.MiRNA-765 mediates multidrug resistance via targeting BATF2 in gastric cancer cells[J]. FEBS Open Bio, 2020, 10(6): 1021-1030.
[10] WANG Shishuo, FANG Yeying, HUANG Jiacheng, et al. Clinical value of microRNA 198-5p downregulation in lung adenocarcinoma and its potential pathways[J].Oncology Letters, 2019, 18(3): 2939-2954.
[11] 邵建斌, 杨梅兰.miR-198 靶向MAPK1 对人乳腺癌MCF-7 细胞增殖和凋亡的调控作用[J]. 中国肿瘤生物治疗杂志, 2018, 25(12):1259-1263. SHAO Jianbin, YANG Meilan. MiR-198 regulates proliferation and apoptosis of human breast cancer MCF-7 cells via targeting MAPK1 [J]. Chinese Journal of Cancer Biotherapy,2018,25(12):1259-1263.
[12] XU Fei, NI Mengdong, LI Jiajia, et al. Circ0004390 promotes cell proliferation through sponging miR-198 in ovarian cancer[J]. Biochemical and Biophysical Research Communications, 2020, 526(1): 14-20.
[13] 张鑫浩, 张涛元, 李俏, 等. 基于GEO 芯片数据的肝癌关键生物标志物的筛选与鉴定及生物信息学分析[J]. 现代检验医学杂志,2020,35(4):26-31. ZHANG Xinhao, ZHANG Taoyuan, LI Qiao, et al.Screening, identification and bioinformatics analysis of key biomarkers for hepatocellular carcinoma based on GEO chip data [J]. Journal of Modern Laboratory Medicine,2020,35(4):26-31.
[14] CHEN Liang, HEIKKINEN L, WANG Changliang, et al. Trends in the development of miRNA bioinformatics tools[J]. Briefings in Bioinformatics, 2019, 20(5): 1836-1852.
[15] SALIMINEJAD K, KHORRAM KHORSHID H R, SOLEYMANI FARD S, et al. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods[J]. Journal of Cellular Physiology,2019, 234(5): 5451-5465.
[16] ZHU Lin, XUE Feng, XU Xiangying, et al . MicroRNA 198 inhibition of HGF/c-MET signaling pathway overcomes resistance to radiotherapy and induces apoptosis in human non-small-cell lung cancer[J]. Journal of Cellular Biochemistry, 2018,119(9): 7873-7886.
[17] 王磊, 师国珍.miR-198 在肝细胞癌组织中的表达[J].中华实用诊断与治疗杂志, 2019, 33(9):904-906. WANG Lei,SHI Guozhen. Expression of miR-198 in hepatocellular carcinoma [J]. Journal of Chinese Practical Diagnosis and Therapy, 2019, 33(9):904-906.
[18] ASHRAFIZADEH M, ANG H L, MOGHADAM E R, et al. MicroRNAs and their influence on the ZEB family: Mechanistic aspects and therapeutic applications in cancer therapy[J]. Biomolecules, 2020,10(7): 1040.
[19] GLOUSHANKOVA N A, ZHITNYAK I Y,RUBTSOVA S N. Role of Epithelial-Mesenchymal transition in tumor progression[J]. Biochemistry(Mosc),2018, 83(12): 1469-1476.
[20] 张青云, 傅俊江, 陈汉春. 上皮间质转化介导肿瘤转移的分子机制[J]. 生命科学研究,2018,22(6):503-510. ZHANG Qingyun, FU Junjiang, CHEN Hanchun. The molecular mechanism of epithelial-mesenchymal transition mediating tumor metastasis [J]. Life Science Research,2018,22(6):503-510.
相似文献/References:
[1]邓旭,王晓亮.肝细胞癌患者血清趋化因子CXCR12和SA的表达及临床意义[J].现代检验医学杂志,2015,30(06):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
DENG Xu,WANG Xiao-liang.Expression and Clinical Significance of Serum CXCR12
and SA in Patients with Hepatocarcinoma[J].Journal of Modern Laboratory Medicine,2015,30(04):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
[2]毛丽萍,何义民,韩 刚,等.血浆Dickkopf同源物1检测对肝细胞癌的诊断价值[J].现代检验医学杂志,2016,31(05):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
MAO Li-ping,HE Yi-min,HAN Gang,et al.Diagnosis Value of Detecting Plasma Dickkopf-1
Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(04):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
[3]阮瑞杨,陈修荣,赵世元.抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义[J].现代检验医学杂志,2017,32(02):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
RUAN Rui-yang,CHEN Xiu-rong,ZHAO Shi-yuan.Expression and Significance of Anti EZH2 Autoantibodies IgG
in Hepatocellular Carcinoma Patient's Serum Samples[J].Journal of Modern Laboratory Medicine,2017,32(04):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
[4]隆绍平,邓世群,赵世元.PTPN12蛋白表达下调与原发性肝细胞癌患者复发和预后关系研究[J].现代检验医学杂志,2018,33(01):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
LONG Shao-ping,DENG Shi-qun,ZHAO Shi-yuan.Association between Downregulation of PTPN12 Protein and Recurrence
and Prognosis in Patients with Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(04):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[5]毛丽萍,王跃国,王 健,等.CMIA法测定血清DCP与AFP对肝细胞癌的诊断价值[J].现代检验医学杂志,2018,33(06):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
MAO Li-ping,WANG Yue-guo,WANG Jian,et al.Diagnostic Value of the Serum DCP and AFP Determined by CMIA in Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(04):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
[6]吴良银a,李文丽b,刘 俊a.肝细胞癌患者生存预后相关长链非编码RNA(LncRNA)的生物信息学分析[J].现代检验医学杂志,2019,34(04):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
WU Liang-yina,LI Wen-lib,LIU Juna.Bioinformatics Analysis of Long-Chain Non-Coding RNA Related
to Survival and Prognosis in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2019,34(04):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
[7]吴良银a,李文丽b,刘 俊b.基于GEO数据的病毒相关性肝癌潜在生物基因标志物的筛选及生物信息学分析[J].现代检验医学杂志,2021,36(06):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
WU Liang-yin,LI Wen-li,LIU Jun.Screening and Bioinformatics Analysis of Potential Biomarkers for Virus-associated Hepatocellular Carcinoma Based on GEO Data[J].Journal of Modern Laboratory Medicine,2021,36(04):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
[8]王 路,叶 莎,韩 霞,等.循环外泌体miRNA 检测对肝细胞癌临床诊断效能的Meta 分析[J].现代检验医学杂志,2022,37(04):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
WANG Lu,YE Sha,HAN Xia,et al.Meta-Analysis of the Diagnostic Value of Circulating Exosomes miRNA Detection for Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(04):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
[9]时晓晓a,董 翔a,于若卉b,等.miR-203a-3p 靶向GLS1 调控HCC 细胞增殖、迁移、侵袭的机制研究[J].现代检验医学杂志,2022,37(05):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
SHI Xiao-xiaoa,DONG Xianga,YU Ruo-huib,et al.Mechanism of miR-203a-3p Targeting GLS1 to Regulate the Proliferation, Migration and Invasion of HCC Cells[J].Journal of Modern Laboratory Medicine,2022,37(04):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
[10]吴翠婷,周雪辉,张婉馨.基于生物学信息分析筛选晚期肝细胞癌患者接受PD-1 抑制剂治疗后糖酵解相关基因差异表达并构建生存获益模型与验证[J].现代检验医学杂志,2023,38(05):34.[doi:10.3969/j.issn.1671-7414.2023.05.007]
WU Cuiting,ZHOU Xuehui,ZHANG Wanxin.Differential Expression of Glycolysis-related Genes in Patients with Advanced Hepatocellular Carcinoma Treated with PD-1 Inhibitors Screened Based on Biological Information Analysis, and Survival Benefit Model Constructed and Verified[J].Journal of Modern Laboratory Medicine,2023,38(04):34.[doi:10.3969/j.issn.1671-7414.2023.05.007]